Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof

摘要

A tumour vaccine is claimed containing tumour cells which themselves present peptides derived from tumour antigens in an HLA content and at least a portion of which have at least one MHC-I-haplotype of the patient on the cell surface, and which have been charged with one or more peptides as defined in the specification in such way that the tumour cells are recognised as foreign by the immune system of the patient in the context of the peptides and trigger a cellular immune response. Charging takes place in the presence of a polycation such as polylysine.